Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1674 | 2007 |
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy JR Dörr, Y Yu, M Milanovic, G Beuster, C Zasada, JHM Däbritz, J Lisec, ... Nature 501 (7467), 421-425, 2013 | 568 | 2013 |
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG AK Buck, G Halter, H Schirrmeister, J Kotzerke, I Wurziger, G Glatting, ... Journal of nuclear medicine 44 (9), 1426-1431, 2003 | 539 | 2003 |
The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer BJ Krause, M Souvatzoglou, M Tuncel, K Herrmann, AK Buck, C Praus, ... European journal of nuclear medicine and molecular imaging 35, 18-23, 2008 | 426 | 2008 |
Spect/ct AK Buck, S Nekolla, S Ziegler, A Beer, BJ Krause, K Herrmann, ... Journal of Nuclear Medicine 49 (8), 1305-1319, 2008 | 425 | 2008 |
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters A Buck, H Schirrmeister, T Kühn, C Shen, T Kalker, J Kotzerke, A Dankerl, ... European journal of nuclear medicine and molecular imaging 29, 1317-1323, 2002 | 367 | 2002 |
Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer H Schirrmeister, G Glatting, J Hetzel, K Nüssle, C Arslandemir, AK Buck, ... Journal of Nuclear Medicine 42 (12), 1800-1804, 2001 | 358 | 2001 |
Gene silencing by adenovirus‐delivered siRNA C Shen, AK Buck, X Liu, M Winkler, SN Reske FEBS letters 539 (1-3), 111-114, 2003 | 335 | 2003 |
3-deoxy-3-[18F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules AK Buck, H Schirrmeister, M Hetzel, M Von Der Heide, G Halter, ... Cancer research 62 (12), 3331-3334, 2002 | 304 | 2002 |
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches AK Buck, K Herrmann, T Stargardt, T Dechow, BJ Krause, J Schreyögg Journal of nuclear medicine technology 38 (1), 6-17, 2010 | 264 | 2010 |
First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary … K Herrmann, M Schottelius, C Lapa, T Osl, A Poschenrieder, H Hänscheid, ... Journal of nuclear medicine 57 (2), 248-251, 2016 | 251 | 2016 |
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state J Den Hollander, S Rimpi, JR Doherty, M Rudelius, A Buck, A Hoellein, ... Blood, The Journal of the American Society of Hematology 116 (9), 1498-1505, 2010 | 251 | 2010 |
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT S Krüger, AK Buck, FM Mottaghy, E Hasenkamp, S Pauls, C Schumann, ... European journal of nuclear medicine and molecular imaging 36, 1807-1812, 2009 | 227 | 2009 |
Inflammation and mitochondrial fatty acid β-oxidation link obesity to early tumor promotion J Khasawneh, MD Schulz, A Walch, J Rozman, MH De Angelis, ... Proceedings of the National Academy of Sciences 106 (9), 3354-3359, 2009 | 226 | 2009 |
68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT C Bluemel, M Krebs, B Polat, F Linke, M Eiber, S Samnick, C Lapa, ... Clinical nuclear medicine 41 (7), 515-521, 2016 | 216 | 2016 |
Molecular imaging of proliferation in malignant lymphoma AK Buck, M Bommer, S Stilgenbauer, M Juweid, G Glatting, ... Cancer research 66 (22), 11055-11061, 2006 | 214 | 2006 |
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma K Philipp‐Abbrederis, K Herrmann, S Knop, M Schottelius, M Eiber, ... EMBO molecular medicine 7 (4), 477-487, 2015 | 213 | 2015 |
Life expectancy is reduced in differentiated thyroid cancer patients≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis … FA Verburg, U Mäder, K Tanase, ED Thies, S Diessl, AK Buck, M Luster, ... The Journal of Clinical Endocrinology & Metabolism 98 (1), 172-180, 2013 | 213 | 2013 |
[68Ga] Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma-Comparison to [18F] FDG and laboratory values C Lapa, M Schreder, A Schirbel, S Samnick, KM Kortüm, K Herrmann, ... Theranostics 7 (1), 205, 2017 | 208 | 2017 |
F‐18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost‐effectiveness, and impact on patient management M Hetzel, C Arslandemir, HH König, AK Buck, K Nüssle, G Glatting, ... Journal of Bone and Mineral Research 18 (12), 2206-2214, 2003 | 201 | 2003 |